Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.

ABSTRACT:

Importance

A neural network-based model (i31-GEP-SLNB) that uses clinicopathologic factors (thickness, mitoses, ulceration, patient age) plus molecular analysis (31-gene expression profiling) has become commercially available to guide selection for sentinel lymph node (SLN) biopsy in cutaneous melanoma, but its clinical utility is not well characterized.

Objective

To determine if use of the i31-GEP-SLNB model is associated with clinical benefit when used to select patients for SLN biopsy.

Design, setting, and participants

This decision-analytic study used data derived from a published external validation study of the i31-GEP-SLNB prediction model. Participants included patients with primary cutaneous melanoma.

Main outcomes and measures

The primary outcome was

SUBMITTER: Marchetti MA 

PROVIDER: S-EPMC9047749 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature